MedTrace Logo

A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors

NCT05389462 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 128

Last updated 2025-05-22

No results posted yet for this study

Summary

The primary objective of this study is to identify the recommended phase 2 dose (RP2D) and/or the maximum tolerated dose (MTD), and characterize the safety and tolerability of ADCT-601 monotherapy and in combination with gemcitabine.

Conditions

Interventions

DRUG

ADCT-601

Intravenous (IV) infusion

DRUG

Gemcitabine

Intravenous (IV) infusion

Sponsors & Collaborators

  • ADC Therapeutics S.A.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-13
Primary Completion
2025-04-17
Completion
2025-04-17
FDA Drug
Yes

Countries

  • United States
  • France
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05389462 on ClinicalTrials.gov